Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-14-132555
Filing Date
2014-04-07
Accepted
2014-04-07 07:06:00
Documents
5
Effectiveness Date
2014-04-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS d706724ddefa14a.htm DEFA14A 33593
2 GRAPHIC g706724notice_pg001.jpg GRAPHIC 163438
3 GRAPHIC g706724notice_pg002.jpg GRAPHIC 217251
4 GRAPHIC g706724notice_pg003.jpg GRAPHIC 87098
5 GRAPHIC g706724notice_pg004.jpg GRAPHIC 75828
  Complete submission text file 0001193125-14-132555.txt   784253
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34186 | Film No.: 14747311
SIC: 2834 Pharmaceutical Preparations